Centerview’s Tokat Sees Potential for Mega Pharma Deals in 2026

A more permissive regulatory environment and Big Pharma’s need to replenish revenue pipelines could spur the first $20 billion-plus M&A drug deal in more than three years, according to Centerview Partners Co-President Eric Tokat.

“If there is a year it will probably be this year or next year quite frankly because the current environment is fairly business friendly from the regulatory perspective and I think people are probably considering whether it makes sense for them to do these larger” deals over $20 billion, Tokat said in a Bloomberg TV interview Wednesday.

A deal that size would be the biggest ...